Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Summary

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Eligibility

Inclusion Criteria:

* Patient older than 18 years age
* Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.

  * Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
  * Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
* ECOG performance status of 0-2
* Life expectancy of 6 months or longer
* Patient able to provide a written informed consent prior to study entry

Exclusion Criteria:

* Prior thoracic radiotherapy to chest.
* Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
* Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Conditions2

Interventions1

Locations3 sites

Find trials near these locations

Related trials

• A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. — David Palma
• AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer — IRCCS San Raffaele
• Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC — Peking University First Hospital
• Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer — The Second Hospital of Shandong University
• Association of Psychological Distress in Patients With Lung Cancer — Shanghai Chest Hospital
• BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases — Shandong Cancer Hospital and Institute
• CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
• Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Browse More Trials